Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2022 | 375 | 4.470 |
Why?
|
| Ovarian Neoplasms | 8 | 2021 | 61 | 3.300 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2021 | 11 | 1.890 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 10 | 1.670 |
Why?
|
| Genes, BRCA1 | 3 | 2020 | 9 | 1.470 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 274 | 1.220 |
Why?
|
| Genes, BRCA2 | 3 | 2020 | 9 | 1.180 |
Why?
|
| Endometrial Neoplasms | 2 | 2021 | 13 | 0.910 |
Why?
|
| Genes, p53 | 3 | 2020 | 16 | 0.900 |
Why?
|
| Genetic Testing | 2 | 2021 | 65 | 0.880 |
Why?
|
| Phthalazines | 2 | 2020 | 8 | 0.870 |
Why?
|
| Female | 24 | 2022 | 17004 | 0.830 |
Why?
|
| Piperazines | 2 | 2020 | 91 | 0.810 |
Why?
|
| Mutation | 4 | 2021 | 407 | 0.790 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 3 | 0.770 |
Why?
|
| RNA Helicases | 1 | 2021 | 1 | 0.770 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2021 | 1 | 0.770 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 4 | 0.710 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 230 | 0.690 |
Why?
|
| Hematopoiesis | 1 | 2018 | 13 | 0.620 |
Why?
|
| Chimerism | 1 | 2018 | 3 | 0.620 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 3 | 0.620 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 2 | 0.620 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 3 | 0.620 |
Why?
|
| Nitriles | 2 | 2017 | 15 | 0.620 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 8 | 0.590 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 10 | 0.590 |
Why?
|
| Humans | 24 | 2022 | 31058 | 0.580 |
Why?
|
| Triazoles | 1 | 2017 | 34 | 0.580 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 32 | 0.580 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 39 | 0.570 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 89 | 0.560 |
Why?
|
| Receptor, ErbB-2 | 3 | 2014 | 49 | 0.550 |
Why?
|
| False Positive Reactions | 1 | 2015 | 36 | 0.510 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 18 | 0.510 |
Why?
|
| Estrogens | 1 | 2015 | 36 | 0.510 |
Why?
|
| Estradiol | 1 | 2015 | 46 | 0.510 |
Why?
|
| Immunoassay | 1 | 2015 | 45 | 0.500 |
Why?
|
| Adult | 10 | 2020 | 8945 | 0.490 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 57 | 0.480 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 11 | 0.480 |
Why?
|
| Middle Aged | 11 | 2021 | 10235 | 0.420 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 269 | 0.410 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2012 | 4 | 0.410 |
Why?
|
| Ribonucleotide Reductases | 1 | 2012 | 1 | 0.410 |
Why?
|
| Platinum | 1 | 2012 | 5 | 0.410 |
Why?
|
| Biopsy | 4 | 2017 | 249 | 0.400 |
Why?
|
| Aged | 8 | 2021 | 10077 | 0.400 |
Why?
|
| Cell Proliferation | 4 | 2021 | 204 | 0.390 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 144 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 77 | 0.390 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 6 | 0.380 |
Why?
|
| Indoles | 1 | 2011 | 50 | 0.370 |
Why?
|
| Protein Kinase C | 1 | 2011 | 47 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 465 | 0.370 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 7 | 0.330 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2008 | 3 | 0.320 |
Why?
|
| Genes, erbB-2 | 1 | 2008 | 7 | 0.320 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 46 | 0.320 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 29 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 115 | 0.310 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2017 | 5 | 0.290 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 404 | 0.270 |
Why?
|
| Retrospective Studies | 4 | 2022 | 3664 | 0.260 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 215 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2022 | 12 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 258 | 0.200 |
Why?
|
| Coculture Techniques | 1 | 2021 | 37 | 0.200 |
Why?
|
| Precision Medicine | 1 | 2021 | 29 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 44 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 79 | 0.190 |
Why?
|
| Fibroblasts | 1 | 2021 | 93 | 0.190 |
Why?
|
| Genomics | 1 | 2021 | 55 | 0.190 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 4 | 0.180 |
Why?
|
| Apoptosis | 1 | 2021 | 260 | 0.180 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 1 | 0.180 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.170 |
Why?
|
| Animals | 2 | 2021 | 4713 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 427 | 0.160 |
Why?
|
| Neoplasm Metastasis | 3 | 2014 | 113 | 0.160 |
Why?
|
| Cadherins | 2 | 2017 | 37 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 104 | 0.160 |
Why?
|
| Pedigree | 1 | 2017 | 75 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2017 | 101 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2015 | 70 | 0.140 |
Why?
|
| Neoplasms | 1 | 2019 | 261 | 0.140 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 2 | 0.140 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 2 | 0.140 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 7 | 0.140 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 7 | 0.140 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 8 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 430 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 80 | 0.130 |
Why?
|
| Liver | 1 | 2017 | 184 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 85 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 25 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 28 | 0.130 |
Why?
|
| Postmenopause | 1 | 2015 | 62 | 0.130 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 2 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 47 | 0.120 |
Why?
|
| Hydroxybutyrates | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2014 | 38 | 0.120 |
Why?
|
| Aniline Compounds | 1 | 2014 | 46 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 71 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5196 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 78 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 103 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2013 | 178 | 0.110 |
Why?
|
| Cell Movement | 1 | 2013 | 105 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 234 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2013 | 152 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 260 | 0.110 |
Why?
|
| Axilla | 1 | 2012 | 15 | 0.100 |
Why?
|
| Deoxycytosine Nucleotides | 1 | 2012 | 1 | 0.100 |
Why?
|
| Thiosemicarbazones | 1 | 2012 | 1 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2012 | 52 | 0.100 |
Why?
|
| DNA Damage | 1 | 2012 | 31 | 0.100 |
Why?
|
| Gynecology | 1 | 2012 | 10 | 0.100 |
Why?
|
| Histones | 1 | 2012 | 28 | 0.100 |
Why?
|
| Pyridines | 1 | 2012 | 47 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2013 | 686 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2012 | 74 | 0.100 |
Why?
|
| Cell Survival | 1 | 2012 | 164 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2012 | 39 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 2 | 0.100 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 8 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 12 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 10 | 0.100 |
Why?
|
| Family | 1 | 2012 | 100 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 81 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 54 | 0.090 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2008 | 3 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Mice | 1 | 2013 | 1681 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2008 | 24 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2008 | 25 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2008 | 43 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 271 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 17 | 0.060 |
Why?
|
| Prognosis | 1 | 2008 | 924 | 0.060 |
Why?
|
| Breast Density | 1 | 2022 | 4 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2012 | 3808 | 0.050 |
Why?
|
| Mammography | 1 | 2022 | 43 | 0.050 |
Why?
|
| Mass Screening | 1 | 2022 | 186 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 9 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 25 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 16 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 224 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 155 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 872 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 1321 | 0.040 |
Why?
|
| Butadienes | 1 | 2014 | 1 | 0.030 |
Why?
|
| Crotonates | 1 | 2014 | 4 | 0.030 |
Why?
|
| Toluidines | 1 | 2014 | 4 | 0.030 |
Why?
|
| Chromones | 1 | 2014 | 8 | 0.030 |
Why?
|
| Morpholines | 1 | 2014 | 15 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 13 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2014 | 17 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 15 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 43 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 21 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 38 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 6 | 0.030 |
Why?
|
| Adalimumab | 1 | 2014 | 16 | 0.030 |
Why?
|
| Mastectomy | 1 | 2014 | 21 | 0.030 |
Why?
|
| Diarrhea | 1 | 2014 | 47 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 73 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 818 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 26 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 33 | 0.020 |
Why?
|
| Male | 1 | 2019 | 16488 | 0.010 |
Why?
|